Johnson & Johnson has announced a definitive agreement to acquire Alios BioPharma, a San Francisco-based, privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.
The acquisition will include Alios BioPharma’s portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in phase II studies for the treatment of infants with respiratory syncytial virus (RSV).
“We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy,” said William N. Hait, M.D., Ph.D., global head, R&D for Janssen, a division of J&J. “AL-8176 complements our existing early stage portfolio for RSV, which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five.”
The transaction is expected to close during the fourth quarter of 2014.